ICILNSEIndo Count Industries Limited· Textiles - CottonMediumNeutral
Announced Fri, 6 Jun · 17:03 IST

Indo Count Industries Limited has informed the Exchange about Transcript

Mgmt Guided Margin PressureMgmt Guided Margin ImprovementPromoter Disclosed Acquisition PlansAnalyst Day Multiyear TargetsMgmt Evaded Key QuestionInvestor Communications View source PDF

ICIL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Indo Count reported FY25 revenue of INR4,191 crores, up 16.4% year-on-year and the highest in company history, but EBITDA margin contracted sharply to 13.7% from 16.7% as strategic US investments and a weak Q4 weighed on profitability. Q4 was particularly disappointing, with EBITDA down 47% year-on-year to INR88 crores, driven by tariff-related demand uncertainty that triggered product down-trading and a roughly 6% drop in average selling price. Management highlighted INR460+ crores of investments over the past 12-15 months into acquisitions (Wamsutta, Fluvitex, Modern Home Textiles, Beautyrest brand) and capacity expansion, including a North Carolina greenfield pillow facility with peak revenue potential of US$85-90 million. The company reaffirmed its target to double revenue to roughly $1 billion by FY28, with $275 million of incremental revenue expected from utility bedding ($175 million) and brand businesses ($100 million). A 100% dividend (INR2 per share) was declared, but management repeatedly declined to provide any forward guidance on volumes or margins citing the volatile tariff environment.

Likely market impact

Near-term sentiment may stay cautious given the steep Q4 margin decline, weak Q1 outlook, and management's refusal to offer FY26 guidance, which could limit near-term upside. However, the diversification into brands and utility bedding, the India-UK FTA tailwind, and a clear medium-term revenue doubling target by FY28 provide a constructive long-term story for patient shareholders.